The shortage years, and what they taught about interruption

The withdrawal trials tested planned, supervised, abrupt discontinuation in people who wanted to be in a trial. Almost nobody in the real world stops that way. They stop because a prior authorisation lapsed, because a formulary excluded the product, because the cash price rose, because the pharmacy had nothing to dispense, because a compounded preparation became unavailable when a shortage listing was resolved, or because the side effects were not worth the benefit. Each of those routes produces a different clinical situation, and the trials illuminate only the last one.

SURMOUNT-4 and the steeper curve

SURMOUNT-4 applied the same architecture to tirzepatide with a longer lead-in. Participants escalated over thirty-six weeks of open-label treatment to their maximum tolerated dose of 10 or 15 mg weekly, achieving a mean reduction of approximately 20.9 per cent, and were then randomised one to one to continue or to switch to placebo for fifty-two weeks.¹

Continuation produced a further mean reduction of about 5.5 per cent, for a total near 25.3 per cent at week 88. Withdrawal produced a mean regain of about 14 per cent of body weight, leaving that arm approximately 9.9 per cent below original baseline. The between-arm difference of roughly fifteen percentage points is similar in magnitude to STEP 4 despite the much larger initial loss.

The steeper regain in absolute terms is the expected consequence of a larger loss rather than evidence of anything peculiar to the agent. It is nonetheless the figure most often quoted without its denominator, and a fourteen-point regain from a twenty-one-point loss is a materially different statement from a fourteen-point regain from a ten-point loss. Both arms in this trial ended below where they began, and the arm that stopped ended roughly where the continued arm of the semaglutide programme did.

The dose-reduction trial that has never been run

Set the three withdrawal trials side by side and a conspicuous absence appears. All three compared a full maintenance dose against placebo. None compared a full dose against a reduced one. The comparison that the great majority of successfully treated people actually face — can I take less of this and hold what I have — has not been randomised at any dose, in any programme, for any agent in this class.

The commercial explanation is straightforward and the Journal states it without much comment: a trial demonstrating that a third of the dose maintains most of the effect would reduce the revenue per treated patient by roughly the same fraction, and sponsors are not obliged to run trials against their own interest. The regulatory explanation is that maintenance dosing falls outside the approved label question, which is whether the product is effective at the studied dose.

The result is that an enormous amount of clinical practice is being conducted on inference. What can be inferred is that the dose-response curve for weight effect flattens at the top of the range, which suggests a step down would cost less than proportionally. Whether the curve is the same shape descending as ascending is unknown, and hysteresis in either direction would not be surprising.

It is worth noting what the one head-to-head weight trial in this class did and did not do. It compared two agents at their respective licensed doses and reported the difference in weight outcome; it did not establish dose equivalence between them, and it cannot be used to convert a maintenance dose of one into a maintenance dose of the other.² Pharmacies asked to substitute during the shortage period had no equivalence basis to work from, whatever the conversion tables in circulation implied.

Resuming after an interruption is a fresh escalation

This is the most practically consequential item in the whole subject and the one least often stated in advance. Gastrointestinal tolerability to these agents develops over weeks of continued exposure and decays when exposure is removed. After four weeks without the drug, plasma concentrations are a small fraction of steady state and the tolerability accommodation has substantially reset. Resuming at the previous maintenance dose therefore presents the system with an exposure step it has not experienced for a month.

The clinical convention — resume at a lower dose and re-escalate — follows from the pharmacokinetics rather than from caution.³ Product labelling for several agents in the class advises consideration of re-initiation at a lower dose after an extended interruption, and the threshold at which this applies differs between products, which is a detail worth checking against the specific label rather than a general rule.

The shortage period demonstrated the consequence of ignoring this at scale. Large numbers of people lost access for six to ten weeks, resumed where they had left off, and experienced nausea and vomiting considerably worse than during their original escalation. It was predictable, it was predicted by anybody who had read the label carefully, and it was almost never communicated.

Cost is the modal reason, and it is missing from the clinical literature

Analyses of pharmacy claims consistently find that persistence with these agents for weight management is poor relative to their efficacy, with a large minority of people no longer filling prescriptions within a year of starting and discontinuation concentrated in the first three months.⁴ The pattern tracks coverage, deductible reset timing and cash price far more closely than it tracks clinical response, which is the signature of an economic rather than a therapeutic discontinuation.

Almost none of this appears in the clinical literature on withdrawal. The trials studied people who stopped because a protocol told them to, with the drug supplied free, in a population willing to be randomised. That is close to the opposite of the situation in which most discontinuation actually occurs: unplanned, unsupervised, at a time set by an insurer or a price rise rather than by a clinical assessment, and frequently without anybody being told it has happened.

The Journal reports discontinuation in both this department and The Ledger for that reason. The clinical trajectory after stopping is a Patient Notes question; why people stop is an economics question; and the two literatures currently do not speak to one another at all.

The supply interruption as a clinical event

A supply gap is a discontinuation with no notice, no plan and no taper. It differs from every other route to stopping in that it is imposed on both the patient and the prescriber, its duration is unknown at the outset, and it frequently ends as abruptly as it began. The shortage listings of recent years produced these events at population scale, and they have not been studied as a clinical exposure.

Three features make them distinctive. The patient cannot plan a maintenance strategy around an interruption of unknown length. Substitution — to a different agent, a different dose, or a compounded preparation — happens under time pressure and often without a dose-equivalence basis, since no head-to-head equivalence data exists between agents in this class. And the resumption problem described above applies in full, because the gaps were typically long enough to reset tolerability.

The Journal reported these events as they occurred and continues to think they represent the largest uncontrolled interruption experiment in the history of the class. What nobody collected was outcome data: how much weight was regained during the gaps, how many people never resumed, and what happened to the glycaemic control of those taking the drugs for diabetes rather than for weight.

When the indication is not weight

The withdrawal question changes shape when the drug was prescribed for something other than weight. In the cardiovascular outcome trial of semaglutide in overweight and obesity without diabetes, the reduction in major adverse cardiovascular events emerged over years of continued treatment, and the trial provides no information about what happens to that benefit on cessation.⁵ The same applies to the renal outcome data in chronic kidney disease with type 2 diabetes, where the effect on kidney disease progression was measured over a median of several years of treatment.⁶

There is no reason to expect an outcome benefit that accrues over years to persist after the exposure ends, and no trial has tested it. For a person taking the drug for glycaemic control, stopping has an immediate and measurable consequence in HbA1c over the following three months. For a person taking it for cardiovascular or renal risk, stopping has no measurable short-term consequence at all, which makes the decision harder rather than easier.

This is the situation in which the Journal thinks the withdrawal-trial coverage has done the most damage. Framing discontinuation as a weight question invites a person taking the drug for kidney disease to reason about it in the wrong currency entirely.

Restarting after a long gap: what to expect

Restarting after months away is well tolerated in general and the response is broadly reproducible: people who lost weight on an agent and stopped generally lose weight again on resuming, at a similar rate. There is no established phenomenon of a diminished second response in this class, and the withdrawal trials that re-offered treatment after their observation periods did not report one.

Three practical features recur. Escalation has to start again from a low dose for tolerability reasons, which means several weeks before the previous maintenance exposure is re-established. The nausea of a second escalation is frequently reported as worse than the first, for which the Journal has seen no mechanistic explanation and would not rule out reporting bias. And the weight trajectory on restarting begins from wherever the person now is, so a second course is a longer project than the first if regain was substantial.

None of this constitutes advice about whether to restart, which is a clinical decision. It is offered as a description of what the trial reports and the correspondence describe, and readers should note that no trial has been designed to study re-initiation as its primary question.

How the Journal reports a regain figure

Four things accompany every regain number in these pages. Which withdrawal design it comes from, because an off-treatment extension and a randomised placebo switch are different experiments. Whether the lifestyle intervention continued in the arm being described. What the denominator is — regain as a percentage of body weight, as a percentage of the weight lost, or as a final position relative to original baseline, three quantities that are routinely quoted interchangeably. And the follow-up duration, because the regain curve decelerates and a figure at six months is not a figure at a year.

The third of those is where most of the misreporting happens. A statement that participants regained two-thirds is a proportion of loss; a statement that they regained eleven per cent is a proportion of body weight; a statement that they finished 5.6 per cent below baseline is a final position. All three can describe the same arm and they are not interchangeable.

Where a source we are quoting has not stated its denominator, we say that rather than inferring it. Readers who find a regain figure in these pages without its design and its denominator have found an error, and the standards desk would like to hear about it at standards@compoundjournal.com.

What this piece is not

This is reporting on a body of trial evidence and it is not advice about whether or how to stop taking a medicine. The decision to discontinue an agent prescribed for glycaemic control, cardiovascular risk or kidney disease is materially different from the decision to discontinue one prescribed for weight, and in every case it belongs with a clinician who has seen the person and knows why the drug was started.

Two further notes. Compounds sold for research use only are not approved for human use in any jurisdiction, and nothing here should be read as guidance about using them or about stopping their use. And where this piece describes what clinicians report doing about maintenance dosing, that is description of practice and not a schedule anybody should adopt from a magazine.

The Journal takes correspondence on this subject at letters@compoundjournal.com and factual challenges at standards@compoundjournal.com. Letters describing a personal experience of stopping are read with attention and are published, where they are published, as accounts rather than as evidence — a distinction this department tries hard to preserve in both directions.

Two practical items follow from the pharmacology rather than from the trials, and only two. An interruption long enough to clear the drug is long enough to reset tolerability, so resumption is a fresh escalation and should be planned as one. And a laboratory panel drawn less than three months after stopping will not yet show the full glycaemic consequence, whatever it turns out to be.